Lupin Pharmaceuticals Inc. (Lupin) and Exeltis USA Inc. have entered into promotional agreement for Exeltis to promote SOLOSEC along with Exeltis’ existing line of Women’s Health products, further enhancing value to OBGYNs and their patients.
SOLOSEC is indicated for the treatment of Bacterial Vaginosis in adult women (a common vaginal infection) and Trichomoniasis in adults (the most common non-viral, curable sexually transmitted infection in the U.S.).
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.
